search
Back to results

Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention

Primary Purpose

Pressure Ulcer

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
PRO-TECT
Sponsored by
David Brienza
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pressure Ulcer focused on measuring Sacral, Overlay Mattress, Cooling

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients 18-100 years of age
  • Patients with Stage 1 or 2 pressure ulcers

Exclusion Criteria:

  • Patients < 18 years old
  • Patients admitted directly to non-critical care beds
  • Patients with undetermined stage or late stage (3 or 4) pressure ulcers
  • Patients with Raynauds disease
  • Patients with spina bifida

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Standard of Care (SOC)

    SOC plus PRO-TECT

    Arm Description

    Patients receive usual or standard of care regarding management of early stage pressure ulcers

    Patients receive usual or standard of care plus the addition of PRO-TECT.

    Outcomes

    Primary Outcome Measures

    Final Pressure Ulcer Stage
    Measure of the severity of the pressure ulcer at the time of discharge

    Secondary Outcome Measures

    Full Information

    First Posted
    December 6, 2015
    Last Updated
    July 15, 2019
    Sponsor
    David Brienza
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02634892
    Brief Title
    Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention
    Official Title
    Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2019
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Funding
    Study Start Date
    July 1, 2019 (Actual)
    Primary Completion Date
    July 1, 2019 (Actual)
    Study Completion Date
    July 1, 2019 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    David Brienza

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Objective - To demonstrate the efficacy of the pressure redistributing cooling mattress overlay compared to usual care in mitigating the progression of early pressure ulcers in critically ill (ICU) patients via a prospective randomized human clinical trial. Specific Aim - The clinical trial will evaluate the efficacy and safety of the PRO-TECT ™ mattress overlay in ICU patients who have already developed early pressure ulcers (Stage 1 and 2) and preventing further progression to more severe pressure ulcers (Stage 3 and 4) as well as potential faster regression (i.e. healing of Stage 1 and 2 pressures).
    Detailed Description
    To demonstrate the efficacy of the pressure redistributing cooling mattress overlay for prevention of pressure ulcers in critical care units, a prospective randomized human clinical trial will be performed. The trial will use functionally equivalent test overlays. The initial pilot clinical trial will evaluate the efficacy and safety of the PRO-TECT ™ mattress overlay in ICU patients who have already developed early pressure ulcers (Stage 1 and 2) and preventing further progression. The trial will be performed in UPMC ICUs by enrolling patients age 18 or older with Stage 1 and Stage 2 sacral/coccyx pressure ulcers. The trial will consist of 2 arms: 1) current usual care (UC) vs. 2) UC + targeted cooling overlay mattress (TCOM). Exclusion criteria will include anticipated ICU length of stay < 3 days, patients initially designated for specialty overlay/bed for pulmonary or bariatric diagnoses, patients with a Stage 3 or 4 or unstageable pressure ulcer on the sacrum. The UC group will receive current UPMC ICU guideline-based care with daily assessments for sacral pressure ulcers. Nursing care guidelines will be applied including frequent patient turning, pressure alleviation, moisture control, and friction relief applications. Patients in this group may receive a specialty bed or overlay mattress without cooling if recommended by wound care specialist. The TCOM group will receive UC plus overlay mattress with targeted sacral cooling. Wound care as well as assessment will be performed daily by the non-wound care nurses ( ie. ICU nurse while under ICU care and Floor nurses while under non-ICU care) as part of their regular daily assessment for both non-target cooling and targeted cooling patients. Wound care specialist will assess the wound on Mon/Wed/Fri for any progression or deterioration of the wounds. These wound care nurses are specialty trained in stage decubitus as well as recommending changes in care to promote healing. Additionally they will record the data as part of their routine care of patient with wounds. Theses types of wound assessments are best performed every 2-3 days in order to see any significant change of therapy and data will be recorded. Data collected on Monday, Wednesday and Friday of each week including Braden score, pressure ulcer stage, healing progression (or deterioration) with measurements (e.g., size), and evidence of infection. Additionally, frequency of patient reposition will be recorded and if not, documentation of justification will be provided. Other data collected will include demographics, vitals, comorbidities, length of times (prior incapacitation at home or nursing facility, transport, emergency department, operative room), ventilation and oxygenation requirement, ventilator days, ICU LOS, need for dialysis, vasopressors, and labs including nutritional labs. Data will be collected until study endpoint of discharge from hospital. Final cost analysis will be performed to compile a cost-benefit of each arm. Accrual will be 6 months.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pressure Ulcer
    Keywords
    Sacral, Overlay Mattress, Cooling

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Standard of Care (SOC)
    Arm Type
    No Intervention
    Arm Description
    Patients receive usual or standard of care regarding management of early stage pressure ulcers
    Arm Title
    SOC plus PRO-TECT
    Arm Type
    Experimental
    Arm Description
    Patients receive usual or standard of care plus the addition of PRO-TECT.
    Intervention Type
    Device
    Intervention Name(s)
    PRO-TECT
    Intervention Description
    Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
    Primary Outcome Measure Information:
    Title
    Final Pressure Ulcer Stage
    Description
    Measure of the severity of the pressure ulcer at the time of discharge
    Time Frame
    at each patient discharged from acute care hospital setting, usually 2-4 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    100 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients 18-100 years of age Patients with Stage 1 or 2 pressure ulcers Exclusion Criteria: Patients < 18 years old Patients admitted directly to non-critical care beds Patients with undetermined stage or late stage (3 or 4) pressure ulcers Patients with Raynauds disease Patients with spina bifida
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    David M Brienza, PhD
    Organizational Affiliation
    University of Pittsburgh
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention

    We'll reach out to this number within 24 hrs